Jed on for Annabel Samimy's questions to Mineralys Therapeutics Inc (MLYS) leadership • Q1 2025
Question
An analyst from Stifel inquired about the potential timing for hypertension guideline updates to include lorundrostat data and whether the primary goal of the Explore-CKD trial is safety, with efficacy expected to be in line with previous studies.
Answer
Executive Jon Congleton could not opine on the specific timing of guideline updates but noted that committees are historically responsive to new innovations. He reiterated that for Explore-CKD, safety is a key element, and the company expects to see a clinically meaningful blood pressure reduction consistent with results from its three prior successful trials, while also gathering more data on the 25mg dose.